SAFC Expands Fermentation Capabilities with Upgrade of Israel Site - - BioPharm International


SAFC Expands Fermentation Capabilities with Upgrade of Israel Site

BioPharm Bulletin

SAFC (St. Louis, MO), a member of the Sigma-Aldrich Group, has announced a $29-million investment to significantly expand its drug substance capabilities in high-potency biologics at the Sigma-Aldrich facility in Jerusalem, Israel. The site enhancement will enable SAFC Pharma to provide process development and cGMP manufacturing to customers requiring large-scale, high-potency, toxic, or hazardous large molecule high potent active pharmaceutical ingredients (HPAPI).

The expansion, scheduled for completion in the first quarter of 2009, will focus production on secondary metabolites, cytotoxins, and large-molecule proteins. A 30,000-sq. ft. area of the new facility has been designed to be Biosafety Level 2 compliant, enabling manipulation of human pathogens. The new capabilities will expand SAFC Pharma’s HPAPI offering to include fermentation-derived HPAPI manufacturing, complementing the multistep organic synthesis flagship facility at its Madison, WI, location.

SAFC release

blog comments powered by Disqus



Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
USP Center in Ghana Receives International Lab Accreditation
August 15, 2014
USP Awards Analytical Research
August 15, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here